A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisTwo trials for ...

Ms. Reid has preexisting psoriasis, an autoimmune disease that can cause itchy ... says BioLab and KIK failed “to properly secure and manage hazardous materials stored on-site, and to properly install ...

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...

A review highlighting the need to improve vitiligo care through understanding the role of the JAK-STAT pathway, early diagnosis ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs.

The phase 3b SPECTREM trial has been evaluating the drug in adults with low body surface area (BSA) moderate plaque psoriasis with special site involvement who had failed topical treatment. Affecting ...

She is an internationally recognized expert in psoriasis and has led over 60 clinical trials and observational studies in psoriasis and other skin diseases. She is the Vice-Chair/Chair-Elect of the ...

Complete clearance of each special site was consistently achieved in the ... 52.9% achieved a Psoriasis Area Severity Index (PASI) 90 response compared to 6.2% of participants who received a ...